list : Chronic Disease
-
Hepatitis C treatment low
Antiviral medicine eliminates hepatitis C in 97% of patients, but Stanford Medicine researchers and colleagues find that many don’t receive the treatment.
-
Possible treatment for mucus-induced lung diseases
Stanford Medicine investigators and their collaborators have designed a compound that’s uniquely capable of blocking excessive mucus secretion — a hallmark of several serious respiratory disorders.
-
Half-million COVID-19 tests at Stanford Medicine
Stanford Medicine, one of the first medical centers in the country to conduct clinical tests for COVID-19, has remained at the cutting edge of coronavirus detection.
-
Study of COVID-19 saliva test
An at-home COVID-19 test, designed by Stanford researchers to be easy to use and provide results within 30 minutes, will be the focus of a study funded by the Stanford Medicine Catalyst Program.
-
Biomarker for lipedema discovered
Researchers have identified a molecule that ties lipedema to other lymphatic diseases, such as lymphedema, and distinguishes it from obesity.
-
Microbial loss, ulcerative colitis linked
Bacteria normally inhabiting healthy people’s intestines — and the anti-inflammatory metabolites these bacteria produce — are depleted in ulcerative colitis patients, a Stanford study shows.
-
Stanford-led teams nab top clinical research prizes
Winning studies were chosen by members of the Clinical Research Forum, a nonprofit foundation that promotes the understanding of clinical research and its impact on health and health care.
-
New incubator for life science innovation
A recently vacated building in Stanford Research Park will be the future home of a new life science incubator and lab suites. Located near campus, this incubator will serve as an anchor for a preeminent life science district.
-
Inflammation turns mutation deadly
A simple viral infection in the lungs of rats can become a lethal form of pulmonary hypertension if a common mutation is present, new Stanford research shows.
-
Success in rheumatoid arthritis trial
In a large trial led by a Stanford investigator, an experimental drug produced clinically meaningful improvements for rheumatoid arthritis patients unresponsive to existing treatments.